Anteris Technologies Global Corp. · NASDAQ:AVR
Anteris Technologies Global — Annual J.P. Morgan Healthcare Conference 2024
25 slides from Anteris Technologies Global's conference presentation, Jan 9, 2024
Slide 1: ASX Announcement: Investor Update Presentation
ASX ANNOUNCEMENT 9 January 2024 Investor Update Presentation BRISBANE, Anteris Technologies Ltd (ASX: AVR) is pleased to provide a copy of an Investor Update Presentation to be held today at the Annual J.P. Morgan Healthcare Conference. ENDS About Anteris Technologies Ltd (ASX: AVR) For personal use
Slide 2: Anteris Team Presentation January 2024
For personal use only Anteris Team Presentation January 2024
Slide 3: Disclaimer
DISCLAIMER Summary information For personal use only This presentation has been prepared by Anteris Technologies Ltd (the “Company”). It is a presentation of general background information in summary form about the Company’s activities current at the date of this presentation. The information does n
Slide 4: Disclaimer cont.
DISCLAIMER CONT. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intent or obligation to update any forward‐looking statements, whethe
Slide 5: For personal use only
For personal use only Anteris has taken a deliberate approach to solving a critical problem. By creating a new class of Aortic valve we have demonstrated superior results in US and European studies. Anteris with its unique and proven technology is on track to be market leader in a USD 10 bn space du
Slide 6: Overview
OVERVIEW The Aortic stenosis market is the largest in Medtech. The space has not had For personal use only any new technology entrants since inception. Anteris identified a clinical gap and designed its product with Physician input to close that gap. The clinical trial results are best in class as a
Slide 7: Market size USD by 2028
MARKET SIZE $USD BY 2028 MARKE For personal use only 13BN Anteris has combined 3 unique technologies (ADAPT ® ,DurAVR™, TAVR MARKET ComASUR™) To create the first new class of treatment for $USD 32K Aortic stenosis in 2 decades. The DurAVR™ valve has ( 16% CAGR ) Current TAVR ASP per unit 16% demonst
Slide 8: Key investment highlights
Key investment highlights Anteris has developed and combined 3 distinct medical technologies to treat the fatal disease, Aortic Stenosis. For personal use only 1 Anteris™ is competing in a forecast US$10-13bn market by 2028 for the treatment of Aortic Stenosis 2 Clinical studies underway are demonst
Slide 9: Compare & Contrast
COMPARE & CONTRAST For personal use only Anteris has created the Existing technologies did first new class of TAVR in not advance with the 2 decades. The product increasing clinical was created to knowledge of Aortic deliberately fill a clinical Stenosis over 20 years. This and strategic gap in the
Slide 10: Market overview | US$13bn+ market opportunity
For personal use only Market overview | US$13bn+ market opportunity The aortic stenosis TAVR Aortic Stenosis + Valve-in-Valve market value(1) patient population is (US$bn) Valve-in-Valve Anteris estimate of 30% the TAVR market under penetrated, Native Aortic Stenosis Current with only ~15-20% of ran
Slide 11: Market overview | Understanding the issue
Market overview | Understanding the issue Anteris has created the first new valve design in over 20 years to treat Aortic Stenosis. For personal use only Treatment options for Aortic Stenosis Overview of Aortic Stenosis (“AS”) Surgical Aortic Valve Replacement (“SAVR”) • Generally includes an open h
Slide 12: The journey of Anteris becoming a structural heart company
For personal use only The journey of Anteris becoming a structural heart company
Slide 13: DurAVR A New Class of TAVR
DurAVR™ A New Class of TAVR Single-piece, native-shaped biomimetic design built to mimic the performance of a healthy aortic valve. For personal use only Caution: Investigational Device. Limited by Federal law to investigational use only. Exclusively for clinical investigations.
Slide 14: Product overview | First-in-class biomimetic TAVR
Product overview | First-in-class biomimetic TAVR Anteris has addressed unmet medical needs with a new class of products for the treatment of aortic stenosis. This first-in-class biomimetic technology can be used for new patients,(USD 10 BN) and replace existing valves in For personal use only patie
Slide 15: Product overview | Patent protected
Product overview | Patent protected Anteris has been issued patents for its ground breaking biomimetic design, which has changed the landscape. For personal use only 14 DurAVR™ THV IS NOT AVAILABLE FOR SALE, FOR CLINICAL INVESTIGATIONAL USE ON
Slide 16: US and European studies
• 50 patients For personal use only • 6 Valve in Valve US and • Primary end points met • Clinical superiority demonstrated as European measured by the defining disease parameters of EOA, MPG studies • Significant improvement in clinical status • Significant improvement in QOL • Significant improveme
Slide 17: Excellent Safety Profile
For personal use only • No death Excellent • No stroke Safety • No permanent pacemaker Profile • No major bleeding/vascular complications • No re-interventions or re-operation
Slide 18: DurAVR delivers excellent haemodynamic results
DurAVR ™ delivers excellent haemodynamic results Consistent Results through 1 Year Continued Haemodynamic Excellence For personal use only First-in-Human US Early Feasibility Study 53 41 2.4 2.2 2.0 2.0 2.0 MPG (mmHg) MPG (mmHg) EOA (cm2) EOA (cm2) Mean annulus: 22.7mm Mean annulus: 22.1mm 0.8 0.7 8
Slide 19: Paradigm Shifting 30-day EFS Hemodynamic Results
Paradigm Shifting 30-day EFS Hemodynamic Results* Mean Annulus size: 22.1 mm For personal use only EOA MPG DVI (Effective Orifice Area) (Mean Pressure (Doppler Velocity Index) 0.63 Gradient) 2.18 7.8 cm2 mmHg No PVL reported at 30-day follow-up (30-day Follow-Up, n=14) *Echo Core Lab Analysis Cautio
Slide 20: Easy to Deliver, Precise Placement and Great PVL Results
Easy to Deliver, Precise Placement and Great PVL Results 100% For personal use only successful delivery 100% 7% 90% Severe 80% 70% 60% Moderate 50% 93% 40% Mild 30% 20% None/Trac 10% e 0% 93% no/trace PVL 7% mild PVL
Slide 21: Clinical data | Cohort 1 and 2 results
Clinical data | Cohort 1, 2 and 3 26 patients are now implanted with DurAVR™, with excellent results that have been maintained over 1 year. For personal use only Baseline characteristics Cohort 1 and 2 Cohort 3 Number of patients n = 13 n=7 Age (years) 73.92 ± 6.4 74.86 ± 4.60 Gender (female) 77% 86
Slide 22: DurAVR is the first AVR shown to restore normal aortic flow
DurAVR™ is the first AVR shown to restore normal aortic flow For personal use only Normal Valve Flow vs DurAVR™: No Significant Difference in Flow (p=0.45) Healthy Aortic Valve Post DurAVR™ THV Flow Displacement (FD) = 12% Flow Displacement (FD) = 14% Flow Reversal Ratio (FRR) = 0% Flow Reversal Rat
Slide 23: DurAVR is a first in class Biomimetic valve that outperforms the market leader
DurAVR™ is a first in class Biomimetic valve that outperforms the market leader Biomimetic performance is needed for a restorative effect. Patients are increasingly younger and need restorative therapy to return to a pre-disease quality and length of life. For personal use only Bioprosthetic Valve B
Slide 24: DurAVR A New Class of TAVR
For personal use only DurAVR™ A New Class of TAVR DurAVRTM biomimetic valve provided Delivery System 30-day EFS result outstanding DurAVRTM EFS results was intuitive and easy to presented at PCR hemodynamic demonstrated excellent use, even with first time London Valve Late performance in safety prof
Slide 25: Thank You
For personal use only THANK YOU anteristech.com 24
Anteris Technologies — Annual J.P. Morgan Healthcare Conference 2024 on 6ix